New hope for lupus patients with lung scarring: telitacicept trial launches
NCT ID NCT07077486
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares telitacicept, a newer biologic drug, against the standard treatment cyclophosphamide for lupus patients who also have interstitial lung disease (ILD). About 100 adults with early lupus and ILD will receive either telitacicept or cyclophosphamide, plus usual care. The main goal is to see which drug better preserves lung function over 52 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Telitacicept (a biologic drug) compared to cyclophosphamide (standard chemotherapy-like drug), both given alongside standard lupus treatments.
- What this could lead to
- If successful, telitacicept could offer a safer, more effective option for managing lupus-related lung disease, potentially reducing reliance on harsh immunosuppressants.
- What could go wrong
- This is a relatively small, early-phase 4 study. Telitacicept may not prove superior to cyclophosphamide, and side effects or lack of lung function improvement are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI catch lung scarring that doctors might miss?
- Can a new biologic tame lupus flares?
- Could a single injection tame lupus and Sjögren's?
- Can a single infusion tame tough lupus?
- Can arm workouts boost oxygen use in lung disease?
- Can a single drug calm three different autoimmune diseases? a new trial puts ATG-201 to the test.